Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NKTR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure of CFO (new) — Interim CFO departing after three years; replacement also interim via consulting firm, suggesting continued lack of permanent financial leadership.
Nektar launches up to $150M at-the-market stock offering as interim CFO transitions
Filed May 8, 2026 · Period ending May 8, 2026 · ~1 min read
Key Changes
-
high
Nektar established an at-the-market offering to sell up to $150 million of common stock through Guggenheim Securities and H.C. Wainwright, with sales at company's discretion. This flexible capital-raising mechanism allows gradual share sales at market prices rather than a single dilutive offering.
Item 1.01 verify on EDGAR → -
medium
Interim CFO Sandra Gardiner retiring May 15 after three years; Linda Rubinstein appointed as new interim CFO via FLG Partners consulting firm at $650/hour. Company continues relying on temporary financial leadership rather than permanent CFO.
Item 5.02 verify on EDGAR → -
medium
Sales agents will receive 3% commission on shares sold under the ATM program. Company retains full control over timing and volume of sales, with no obligation to sell any shares. Agreement can be terminated by either party with notice.
Item 1.01 verify on EDGAR → -
low
New interim CFO Rubinstein brings 35+ years of life sciences experience, most recently serving as CFO of Adverum Biotechnologies through its 2025 sale to Eli Lilly. Consulting arrangement has indefinite term with 15-day termination notice.
Item 5.02 verify on EDGAR →
Summary
Nektar Therapeutics announced two significant developments on May 8, 2026. The company established a up to $150 million at-the-market equity offering facility with Guggenheim Securities and H.C. Wainwright, giving management flexibility to raise capital by selling shares gradually at prevailing market prices.
This is a common financing tool for biotech companies, allowing them to access capital without the immediate dilution of a traditional stock offering. Nektar retains full discretion over whether and when to sell shares. Simultaneously, the company announced a CFO transition. Sandra Gardiner, who served as interim CFO since April 2023, is retiring effective May 15.
Linda Rubinstein, also from consulting firm FLG Partners, will take over as interim CFO. Rubinstein's credentials are strong—she recently guided Adverum Biotechnologies through its sale to Eli Lilly—but the continued reliance on interim leadership raises questions about financial stability and strategic direction. Retail investors should monitor two things: actual share sales under the ATM program (disclosed in quarterly reports) to gauge dilution impact, and whether Nektar eventually appoints a permanent CFO, which would signal greater organizational stability and long-term planning confidence.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 8, 2026, Nektar Therapeutics (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”) with Guggenheim Securities, LLC (“Guggenheim Securities”) and H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”) having an aggregate offering price of up to $150,000,000 (the “Shares”), through Guggenheim Securities and Wainwright as its sales agents.
Nektar established an at-the-market offering facility allowing it to sell up to $150 million of common stock over time through two investment banks acting as sales agents. This is a flexible capital-raising mechanism where shares can be sold gradually at prevailing market prices rather than in a single large offering. The company is not obligated to sell any shares and retains full discretion over timing and amounts.
Added in current filing · verify on EDGAR →
The Company will pay Guggenheim Securities and Wainwright a commission fee of 3.0% of the gross sales price of any Shares sold through Guggenheim Securities and Wainwright, as applicable, under the Agreement, and also has provided Guggenheim Securities and Wainwright with customary indemnification and contribution rights.
The sales agents will receive a 3% commission on any shares sold, which is a standard fee for at-the-market offerings. The company also granted customary legal protections to the agents. Neither the company nor the agents are required to execute any sales, and either party can suspend or terminate the arrangement.
Added in current filing · verify on EDGAR →
The issuance and sale, if any, of the Shares may be by any method permitted by law deemed to be an “at-the-market offering” as defined in Rule 415 of the Securities Act of 1933, as amended, including by means of ordinary brokers’ transactions on the Nasdaq Capital Market at market prices or otherwise at prices related to prevailing market prices or at negotiated prices, by privately negotiated transactions (including block sales) or by any other methods permitted by applicable law.
Shares can be sold through various methods including regular broker transactions on Nasdaq at market prices, negotiated prices, or block sales. This flexibility allows Nektar to optimize timing and pricing based on market conditions. Sales will occur under the company's existing shelf registration statement filed in November 2025.
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 7, 2026, the Company announced that Sandra Gardiner will be retiring and stepping down as interim Chief Financial Officer of the Company, effective May 15, 2026. Ms. Gardiner, a partner of FLG Partners, LLC, a leading chief financial officer services firm (“FLG”), has served as interim Chief Financial Officer of the Company since April 2023.
Sandra Gardiner is retiring as interim CFO effective May 15, 2026, after serving in the role since April 2023. She is a partner at FLG Partners, a CFO services firm, and will continue to support the transition as necessary.
Added in current filing · verify on EDGAR →
Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.
Linda Rubinstein, also a partner at FLG Partners, will become interim CFO on May 15, 2026. She has over 35 years of experience in life sciences and investment banking, most recently serving as CFO of Adverum Biotechnologies through its 2025 sale to Eli Lilly. The company continues to rely on interim CFO services from a consulting firm rather than hiring a permanent CFO.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Pursuant to the Agreement, FLG will be paid $650 per hour, subject to any changes that the Company and FLG may agree to from time to time for Ms. Rubinstein’s services.
The company amended its consulting agreement with FLG Partners to pay $650 per hour for Rubinstein's CFO services. The agreement has an indefinite term and is terminable by either party with 15 days' notice, indicating continued reliance on temporary financial leadership.
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Equity Distribution Agreement, dated May 8, 2026, by and among Nektar Therapeutics, Guggenheim Securities, LLC and H.C. Wainwright & Co., LLC.
Nektar Therapeutics entered into an equity distribution agreement on May 8, 2026 with two underwriters, Guggenheim Securities and H.C. Wainwright. This type of agreement typically establishes an at-the-market (ATM) offering program allowing the company to sell shares directly into the market over time to raise capital. The filing does not specify the maximum dollar amount or share count that may be sold under this program.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify